Compare Summit Therapeutics Inc (SMMT) vs Workiva Inc (WK) Price & Performance

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

Workiva (WK) trades at $73.25, up 2.4% with strong bullish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $885M in 2025 to $966M in 2026 and a shift to profitability with net income of $47M. Recent earnings beats and analyst optimism (16 buy ratings) support the positive momentum, though high valuation ratios (P/E 87.73) suggest premium pricing.

Outlook remains positive with consensus price target of $86 offering 17% upside potential. Key risks include elevated valuation metrics and competitive pressures in the regulatory technology space. The company's AI innovations and inclusion in analyst 'top picks' lists provide growth catalysts, but investors should monitor execution against high expectations.